Litigation concerned non-incisional permanent birth control procedure.
Japan's top drug maker sues Mylan Pharmaceuticals, Watson Pharmaceuticals and Ranbaxy Laboratories over their generic versions of ACTOS (pioglitazone HCl).
Dispute over patents for processes for encapsulation by gelatin-free polymeric materials.
Lundbeck has been fending off generics makers with production patents.
Critics claim law would criminalize innocent conduct and extend drug patents another 18 months.
Declaration seeks to define the ethical principles that should govern the collection, processing, storage and use of human genetic data.
Commission will ask court to grant generics makers licensing rights and levy fines against makers of anti-HIV drugs.
Court finds generics maker can market drug even after original is pulled.
Judge declares four Corixa patents unenforceable due to inequitable conduct.
Union head proposes reducing 20-year patent protection period and integrating all prescription drugs into a revised Canada Health Act.
Speed of approval would depend on complexity of drug, executive predicts.
Common system would greatly reduce applications and processing time across 21-nation region.
Case concerns right of U.S. health information provider NDCHealth to demand a licence to the marketing database of rival IMS Health.
In a setback for large pharma and biotech companies, alternative route could be used to approve the first generation of generic biotechnology drugs.
Roxane drops challenge to patent and agrees not to seek approval to market product until patent expires in 2014.
Lundbeck agrees to licence patents to Sandoz for certain territories and pulls claims of forgery and perjury against Matrix Laboratories.
Proposals would ban patents on diagnostic, therapeutic and surgical methods.
Ortho Tri-Cyclen Lo oral contraceptive has $110 million in annual sales.
Ontario argues that a gene molecule is patentable but not the genetic information contained in the molecule.
Genzyme had already withdrawn from suit in settlement one day earlier; Mount Sinai not expected to pursue case further.